Celcuity+Logo.jpg
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity+Logo.jpg
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
February 22, 2024 16:05 ET | Celcuity Inc.
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient...
Celcuity+Logo.jpg
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
February 20, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Orion Group Financia
Orion Group Financial Statement Release January–December 2023
February 13, 2024 05:00 ET | Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1-12/2023            13 FEBRUARY 2024 at 12:00 EET Orion Group Financial Statement Release January–December 2023 Net sales totalled EUR 1,189.7...
Yiviva and AstraZeneca Strategic Collaboration Memorandum Signing Ceremony
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
February 05, 2024 09:00 ET | Yiviva
NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed...
Oncternal.png
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
January 08, 2024 09:00 ET | Oncternal Therapeutics
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
22157.jpg
Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032
January 04, 2024 18:33 ET | Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
Oncternal.png
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
October 05, 2023 16:01 ET | Oncternal Therapeutics
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Celcuity+Logo.jpg
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
August 22, 2023 16:05 ET | Celcuity Inc.
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Orion and Bayer expa
Orion and Bayer expand clinical development program for darolutamide in prostate cancer
March 23, 2023 09:00 ET | Orion Oyj
ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET                      Orion and Bayer expand clinical development program for darolutamide in prostate cancer Phase III study ARASTEP...